Furthermore, bortezomib upregulates NKG2D in NK cells and DNAM-1-related ligands in myeloma cells by activating ataxia-templated mutation and RAD3-related protein (ATR)-dependent senescence program (Soriani et al., 2009; Niu et al., 2017). The gene discussed is KLRK1; the disease is plasma cell myeloma.